Are Cell Therapy Leaders Losing Their Innovative Edge? Spotlight on Gilead (Blast 5/6)
As the cell therapy field continues to grow and evolve, companies are developing innovative strategies to overcome the current challenges that the field is facing. In our Spotlight blasts 1-2 and 3-4, the Celltelligence team discussed Novartis’s and BMS’s pipeline, manufacturing technology, novel platforms, and potential strategy for maintaining an innovative clinical program:
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.